Syncom Formulations (India)'s Q3 FY 2025-26 Quarterly Results
- 13 Feb 2026
Result Summary
- Syncom Formulations (India) Ltd reported a 5.0% quarter-on-quarter (QoQ) decrease in its consolidated revenues for the quarter-ended Dec (Q3 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a decline of 8.3%.
- Its expenses for the quarter were down by 8.9% QoQ and 16.4% YoY.
- The net profit increased 13.9% QoQ and increased 45.5% YoY.
- The earnings per share (EPS) of Syncom Formulations (India) Ltd stood at 0.23 during Q3 FY 2025-26.
Financial Statments for Q3 FY 2025-26
Total Income | 120.64 | 126.97 | 131.57 | -5.0% | -8.3% |
Total Expenses | 95.55 | 104.93 | 114.31 | -8.9% | -16.4% |
Profit Before Tax | 25.09 | 22.04 | 17.26 | 13.8% | 45.4% |
Tax | 6.18 | 5.44 | 4.26 | 13.6% | 45.1% |
Profit After Tax | 18.91 | 16.60 | 13.00 | 13.9% | 45.5% |
Earnings Per Share | 0.23 | 0.18 | 0.14 | 27.8% | 64.3% |
Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results
Company Overview
Syncom Formulations (India) Ltd is a company operating in the pharmaceutical industry, primarily engaged in the manufacturing and distribution of pharmaceutical formulations. The company focuses on producing a wide range of medicinal products including tablets, capsules, syrups, and other dosage forms. As of the latest available data, Syncom Formulations is known for its contribution to various therapeutic segments, though specific details on recent major developments are not provided in the financial data. Being a part of a competitive and essential industry, the company's financial performance is crucial for understanding its market position and operational efficiency.
Revenue
In the third quarter of the fiscal year 2026 (Q3FY26), Syncom Formulations (India) Ltd reported a total income of ₹120.64 crores. This reflects a quarter-over-quarter (QoQ) decrease of 5.0% compared to the ₹126.97 crores recorded in Q2FY26. Year-over-year (YoY), the total income declined by 8.3% from ₹131.57 crores in Q3FY25. Such changes in revenue highlight the dynamic nature of the company's sales and operational environment across different periods. The company's ability to generate revenue consistently over time is a critical aspect of its financial health and market competitiveness.
Profitability
For Q3FY26, Syncom Formulations (India) Ltd achieved a profit before tax of ₹25.09 crores, showing a QoQ increase of 13.8% from the previous quarter's ₹22.04 crores. Compared to the same quarter in the previous year, there was a significant YoY increase of 45.4% from ₹17.26 crores. After accounting for taxes, the profit after tax stood at ₹18.91 crores in Q3FY26, an improvement from ₹16.60 crores in Q2FY26 and ₹13.00 crores in Q3FY25, marking a QoQ increase of 13.9% and a YoY increase of 45.5%. These figures demonstrate the company's ability to maintain profitability despite fluctuations in total income, with tax expenses also increasing by 13.6% QoQ and 45.1% YoY to ₹6.18 crores in Q3FY26.
Operating Metrics
In Q3FY26, Syncom Formulations (India) Ltd's total expenses were recorded at ₹95.55 crores, which is a decline of 8.9% QoQ from ₹104.93 crores in Q2FY26 and a decrease of 16.4% YoY from ₹114.31 crores in Q3FY25. The reduction in expenses indicates an adjustment in the company's operational costs. Earnings per share (EPS) for the quarter were ₹0.23, which grew by 27.8% QoQ from ₹0.18 and by 64.3% YoY from ₹0.14. The EPS growth reflects the company's enhanced profitability on a per-share basis, which can be significant for investors and stakeholders analyzing the company's financial performance over time.